This is an interesting study looking at a synaptic PET marker (SV2A) in patients with schizophrenia and controls. This is important as genetic studies have highlighted synaptic processes in schizophrenia (and related disorders). So this provides a pathological measure. THey also pair this with an animal study in an attempt to show that the observed effects are not simply due to medication. THis is an important addition. I have a few comments:
1. The authors correctly highlight that genetic studies in schizophrenia point to synaptic pathways. However the claim that there is a specific link to SV2A is not confirmed in substantive studies and should be removed.
2. They have controlled for medication effects in the animal study. Can they provide reassurance that there are no correlations of the signal with other potential confounds eg smoking, other medications apart from antipsychotics etc? (the latter should be listed).
3. There are no correlations with Grey matter-have the authors examined correlations with measures of white matter?
4. WHat is know in terms of how SV2A levels relate to synaptic function overall? What aspects is being assessed here? Is it "number of synapses" or specific aspects of function -this could be made clearer.
Could the lack of significant findings in the Hippocampus represent the quality of the signal from this brain region?
Reviewer #2 (Remarks to the Author):
In this interesting manuscript the authors report the first study on SV2A PET imaging in patients with schizophrenia. The study was performed by researchers which have significant experience in the field of schizophrenia and brain imaging. The experiments took a translational approach, including an evaluation of potential anti-psychotic treatment effects on SV2A examined in animals. The sample size in the clinical study (16 schizophrenia and 16 control volunteers) and the animal study (n=3-12 per group) were of reasonable size for these type of study designs. The imaging and biochemical studies were performed with appropriate methodologies and were reported in good detail. Overall, the study was of high quality and provides important insight in in vivo SV2A changes in schizophrenia (although no correlations were found with clinical symptoms).
My main comments: 1) A more detailed summary of the studied subjects (e.g. clinical assessment details) should be added. For instance, there was no group effect on the corrected grey matter volumes (cGMV), which is different than several reports in the literature. Could this be related to the particular group of schizophrenia volunteers studies, could they be due to methodological differences (e.g. use of FreeSurfer) or are they related to something else? 2) Vt was used as the main outcome measure in the PET studies. It has however been shown that the white matter contains minimal SV2A, and that the centrum semiovale may be used as a reference region for [11C]UCB-J (Koole et al, 2019, EJNMI). Since Vt typically has larger intersubject variability when compared to DVR-1, did the authors consider using a reference region approach for quantification of [11C]UCB-J? How did the Vt values of the white matter compare? It would be helpful for the reader if these values were included. 3) SV2A plays a role in exocytosis, and the effect of exocytosis on the binding of [11C]UCB-J seems so far unclear. In the current study design, the animal study does not control for a D2R drug treatment effect on exocytosis and potential following effect on in vivo [11C]UCB-J binding. The effect of exocytosis on [11C]UCB-J binding should thus also be discussed as another possible reason for the group difference in Vt.
Additional comments: 1) How were the secondary ROIs selected? 2) Where the groups matched for smoking status? 3) Figure 2 , in the Western blot results the ratio of SV2A/GAPDH is relatively low, 0.05-0.1. Did the authors also compare the uncorrected SV2A intensities? 4) Line 296, the Vt value also includes the free radiotracer concentration, in addition to the specific and nonspecific binding. 5) Line 297, the proportion of Vt reflecting specific binding relates to the regional SV2A density. In which brain region does 80% of Vt account for specific binding? 6) Line 353, should also refer to the loss of SV2A in MDD, reference 76. 7) Line 480, what time window corresponds to the 14th frame? 8) Line 486, where the brain volumes determined using FreeSurfer? 9) The authors interpret SV2A binding as a marker of synaptic proteins and as a proxy marker for nerve terminals. It is not discussed how SV2A is distributed across neurons from different neurotransmitters (e.g. glutamatergic vs. Gaba-ergic), and the authors should discuss this in further detail.
Reviewer #3 (Remarks to the Author):
Onwordi and colleagues present the findings of two complementary studies supporting the synaptic hypothesis in schizophrenia. In the clinical study, the authors examined 16 patients with schizophrenia and 16 healthy controls using a novel PET ligand for synaptic vesicle glycoprotein 2A (SV2A). To control for the possible effects of antipsychotic treatment, the authors performed a parallel animal study. They investigated the effects of haloperidol and olanzapine on SV2A levels in Sprague-Dawley rats, showing no significant effects. Though this is a relatively small study, the investigators present compelling in vivo evidence for the presence of decreased levels of a synaptic protein in frontal and anterior cingulate cortices in the brains of patients with schizophrenia and show that this is likely not caused by the antipsychotic treatment, but rather the disease itself. This study addresses an important question (whether patients with schizophrenia exhibit decreased levels of synaptic proteins) using a novel imaging technique. This report is an important addition to the literature, with the following suggestions for improvement. 6. Please provide more clinical descriptive details. This is important for reproducibility, since clinical features of patient samples can vary widely, and those clinical features may be associated with biological measures like synaptic density. I suggest at least the following clinical variables should be described, if available: PANSS sub-scales, other concomitant medications (besides antipsychotics), age of onset of psychosis, family history of psychosis, duration of illness, nicotine/smoking status, co-morbid DSM diagnoses (anxiety, depression, OCD, past substance use disorder, etc).
7. If previous studies have validated the specificity of the SV2A polyclonal antibody and the UCB-J ligand, please cite them.
8. Nicotine use often differs between schizophrenia and control samples. Please report nicotine/tobacco use for the two groups and, if needed, address this potential confounder in the Discussion.
9. The groups are well matched in terms of age and gender. However, both groups are predominantly male. Were sampling procedures biased toward men? Are sex differences expected in the variables measured? Are UCB-J PET data available comparing women vs men? How does this imbalance affect interpretation and generalizability? This limitation should be stated in the Abstract and addressed in the Discussion.
10. Line 49 -I would recommend specifying "positive" symptoms, in contrast to negative symptoms, rather than the formulation "psychotic, cognitive, and negative."
11. Line 69-71 -The authors cite studies showing lower brain volumes and altered functional connectivity in schizophrenia as indirect evidence for altered synaptic function, but there many other potential explanations for these findings, e.g., excitotoxicity/ medication effects accounting for lower volumes, white matter changes leading to altered anatomical connectivity, leading in turn to altered functional connectivity.
12. Line 81 -The term "synaptic dysfunction" is used in several places in the manuscript. Since the experiments presented do not measure SV2A or brain function, I would advise using this term with care. While the data do support the "synaptic dysfunction" hypothesis (Abstract), these experiments do not strongly or directly test differences in function (line 81).
13. Line 83 -Frontal cortex, ACC, and hippocampus are all paired structures. Did the authors hypothesize any lateralized effects?
14. Line 85 -The meaning of "indirectly associated" is unclear.
15. Line 108 -The authors state that "all volunteers with schizophrenia were on dopamine D2 receptor antagonist medication". This is technically not true, since one patient is on a partial agonist, aripiprazole. It might be better to use a more general term, such as "antipsychotics".
16. Line 185 -How does the length of exposure of rats -28 days (elsewhere in the text, the authors point out this is roughly equivalent to 2.4 human years) -compare to the length of time the human subjects have been exposed to antipsychotics?
17. Lines 421-422 -Please specify what is meant by "schizophrenia spectrum disorders" 18. Line 431 -Were volunteers with schizophrenia diagnosed with the SCID, or was it a clinical diagnosis? Who performed the assessments and administered the scales? Psychiatrists? Non-MD raters? One or multiple? If there were more than one rater, did the authors measure inter-rater reliability?
19. Line 777 (Supplemental Table 1 ) --5 of the 16 patients were on clozapine, which raises questions about treatment resistance, and duration of illness. Did treatment resistant patients or patients on clozapine have different VT than the non-treatment resistant ones?
Dear Reviewers, Thank you for your review of our manuscript.
The manuscript has been revised to incorporate all of the suggestions put forward.
We have addressed the points that you have raised, with our itemized response attached herewith. We hope the revised version will meet your approval.
Yours sincerely,
The authors.
Reviewers' comments:
Reviewer #1 (Remarks to the Author): This is an interesting study looking at a synaptic PET marker (SV2A) in patients with schizophrenia and controls. This is important as genetic studies have highlighted synaptic processes in schizophrenia (and related disorders). So this provides a pathological measure. THey also pair this with an animal study in an attempt to show that the observed effects are not simply due to medication. THis is an important addition. I have a few comments:
>> We thank the reviewer for this comment. Multiple studies report variants in genes encoding synaptic proteins in schizophrenia. In support of this, we referred to one study that identified a single nucleotide polymorphism in SV2A associated with schizophrenia 1 . It is the case, however, that this finding has not been replicated, nor has it been identified in the GWAS data. In light of this, we have qualified our claim such that the text in the introduction now reads as follows:
Genetic studies have found associations between schizophrenia and variants in genes encoding synaptic proteins [2] [3] [4] (the latter should be listed).
>>We thank the reviewer for their considerations regarding the potential effects of smoking and other medications. We have added in additional information on smoking and concomitant medications, conducted additional analyses, and amended the discussion to address this as follows:
Amendment to the results section:
We conducted exploratory analyses to explore the potential influence of smoking, concomitant medication and clozapine treatment on V T . These showed no significant effect of these variables on V T (see Supplementary Notes). [7] [8] [9] . Furthermore, data from our preclinical study confirmed the lack of and E). Thus we believe that this analysis would not be informative.
WHat is know in terms of how SV2A levels relate to synaptic function overall?
>>We thank the reviewer for this question, and have updated the discussion section to reflect our answer as follows:
Notwithstanding the discussion above on whether our findings reflect a specific loss of SV2A or indicate lower synaptic terminal levels, lower SV2A levels may also have functional consequences. SV2A plays a key role in neurotransmitter exocytosis from vesicles into the synaptic cleft 10 . SV2A knock-out in mice results in deficits in action potential-induced GABAergic neurotransmission 11 , and pharmacological modulation of SV2A function alters post-synaptic excitatory and inhibitory potentials 12 . Moreover, SV2A levels in the dorsolateral prefrontal cortex indexed using [ 11 C]UCB-J are negatively associated with functional connectivity between that region and the posterior cingulate cortex in patients with affective disorders 6 . Thus, lower SV2A levels could have functional consequences, theoretically altering excitatory-inhibitory balance, thereby impairing interactions between neuronal systems and contributing consequently to the dysconnectivity observed in schizophrenia 13, 14 , although this requires testing.
5.What aspects is being assessed here?
Is it "number of synapses" or specific aspects of function -this could be made clearer.
>> We assessed levels of SV2A, which is both a marker of synapses, but also has a functional role. To address the reviewer's comment, we have elaborated in the discussion of the revised version on the relationship between SV2A levels and synaptic density vs synaptic function as requested, as shown below:
Non-human primate studies show a strong positive relationship between [ 11 C]UCB-J V T and in vitro SV2A levels determined using western blots (r>0.8) and binding assays (r>0.9) 7 .
Moreover, displacement studies 7,9,15 using levetiracetam, a drug that binds selectively to SV2A 16 , show the [ 11 C]UCB-J signal is blocked substantially, indicating specificity to SV2A. This evidence indicates that [ 11 C]UCB-J is a specific marker of SV2A levels, and thus that SV2A levels are reduced in schizophrenia. SV2A, one of 3 isoforms of SV2, is ubiquitously expressed throughout the brain and is present in GABAergic and glutamatergic presynaptic nerve terminals 17 . Furthermore, SV2A levels are strongly, positively correlated with synaptophysin levels in the brain (r>0.95) 7 , which is reduced in disorders associated with synaptic loss 7, 18 and is widely used as a marker of synaptic density. With 5 copies per synaptic vesicle, SV2 shows much lower variability in this regard than synaptophysin 19 .
[ 11 C]UCB-J PET has demonstrated sensitivity to synaptic reductions in temporal lobe epilepsy and Alzheimer's disease 7, 18 , and has provided evidence consistent with synaptic alterations in affective disorders 6 . Thus, the lower [ 11 C]UCB-J uptake we observe in schizophrenia could be due either to a reduction in SV2A levels specifically, or a reduction in nerve terminal number manifest as decreased levels of SV2A and other synaptic protein levels. SV2A transcript levels have been reported to be lower in the cerebellar cortex in schizophrenia post-mortem 20 but, to our knowledge, there have not been studies in the FC, ACC or hippocampus and this does not preclude a reduction in synaptic terminal number as well. Moreover, when our findings are taken with evidence of reductions in other synaptic vesicle proteins [21] [22] [23] [24] [25] [26] , cortical neuropil 27 , cortical dendritic spine density [28] [29] [30] , and spine plasticity 31 coupled with unaltered neuronal numbers in schizophrenia 32 , the most parsimonious explanation is that they reflect lower synaptic terminal density. A reduction in synaptic terminals could be due to a developmental failure to form synapses and/or excess synaptic pruning in schizophrenia 33, 34 , potentially linked to microglial mediated mechanisms 5, 35, 36 .
Could the lack of significant findings in the Hippocampus represent the quality of the signal from this brain region?
>> We thank the reviewer for this comment. It is certainly possible that significant differences in [ 11 C]UCB-J V T may be harder to detect in the hippocampus because the specific signal is lower compared to those of the frontal and anterior cingulate cortices.
To address this point, we have now amended the discussion to consider this issue and have also conducted additional analyses using distribution volume ratio (DVR), which has a higher signal to noise ratio than V T (see reviewer 2 point 3), and so is more sensitive to differences.
These additional analyses do show a significant difference in the hippocampus, consistent with the reviewer's point that the lack of significant difference with V T could be due to lower signal to noise in the hippocampus. We have amended the manuscript to include this additional discussion and analysis as follows:
Amendment to the introduction:
Furthermore, we performed an exploratory analysis to test whether effects are generalised to other brain regions (occipital, parietal and temporal lobes, dorsolateral prefrontal cortex, thalamus and amygdala) where structural and/or functional alterations have been identified in schizophrenia using in vivo neuroimaging [37] [38] [39] , and we calculated distribution volume ratio in each region of interest, using the centrum semiovale as a pseudoreference region for estimates of nondisplaceable binding of
Amendment to the method:
The CIC atlas was also used to define the dorsolateral prefrontal cortex, temporal, parietal and occipital lobes, thalamus and amygdala as additional ROIs for the exploratory analysis of effects in other brain regions. The centrum semiovale ROI was generated from the automated anatomical labelling template 40 according to parameters defined for its use as a reference region for nondisplaceable binding of [ 11 C]UCB-J 7 .
Furthermore, DVR was obtained by use of the centrum semiovale as a pseudoreference region as previously described 7, 8 .
Amendment to the results: 
[ 11 C]UCB-J DVR across groups in exploratory ROIs
There was a significant effect of group ( Supplementary Figures 7 and 8 ).
Amendment to the discussion:
Moreover, in contrast to post-mortem studies, we were able to examine multiple regions in each individual, and find evidence for regional differences in the magnitude of effects, given the finding of a significant group-by-region of interest interaction effect. We found lower [ 11 C]UCB-J V T across multiple brain regions, but also evidence that frontal cortical regions may be more affected than hippocampus. The results were largely the same when using an alternative outcome measure, the distribution volume ratio (DVR), which uses a brain region, the centrum semiovale, that is thought to be largely devoid of SV2A as a reference region to adjust for non-specific binding 7 . The one exception was the hippocampus, where DVR was significantly lower in the schizophrenia group relative to controls, albeit the effect size in the hippocampus was not as large as those in the other regions. This difference between the V T and DVR results for the hippocampus may reflect the fact that DVR values show lower variability and so are likely to have greater sensitivity to detect group differences 41, 42 , and our study lacked sufficient power to detect smaller effect size differences in hippocampal V T .
Thus, our finding that effects are less marked in the hippocampus relative to the frontal cortex warrants confirmation in future studies. 
My main comments:
1) A more detailed summary of the studied subjects (e.g. clinical assessment details) should be added.
>> We thank the reviewer for this comment. We have provided additional details of the recruitment, and clinical assessment of the patients as follows:
Methods
We recruited 18 individuals with a DSM-5 diagnosis of schizophrenia from community mental health services in London. 18 healthy volunteers were recruited through public advertisement.
and
The healthy volunteers were screened to exclude any family history of psychosis.
We have also added a new table to provide further clinical details (see supplementary table   2 ). Please see also the additional clinical information provided in response to reviewer 1, comment. 2.
2) ….there was no group effect on the corrected grey matter volumes (cGMV), which is different than several reports in the literature. Could this be related to the particular group of schizophrenia volunteers studies, could they be due to methodological differences (e.g. use of FreeSurfer) or are they related to something else?
>>Thank you for highlighting this issue. In absolute terms grey matter volumes were lower in our schizophrenia sample relative to controls but this was not significant. Meta-analyses typically report grey matter volume reductions of small-to-medium effect size and heterogeneity in the grey matter volume changes between patients 37, 43 . Studies using
Freesurfer have reported significantly lower grey matter volumes in schizophrenia 44 , suggesting that this method is able to detect differences. Thus, the lack of significant differences in our sample most likely reflects the relatively small changes in grey matter volume generally seen in schizophrenia coupled with heterogeneity between patients. We have now amended the discussion as follows:
Lower grey matter volumes are reported in the FC and ACC in schizophrenia 37 , indicating partial volume effects could contribute to our findings. That we found no significant alterations in regional corrected grey matter volume likely reflects the small-to-medium effect size reductions in volume relative to healthy controls and heterogeneity in the alterations between patients 37 , and crucially limits confounding partial volume effects. To further answer this point, regarding particularly the suitability of the centrum semiovale as a reference region for >> We thank the reviewer for this constructive feedback. We have amended our discussion of the results to include evidence that SV2A may regulate Ca
2+
-dependent exocytosis in the presynaptic nerve terminal 48 and that the effect of exocytosis on [ 11 C]UCB-J binding is unclear. We also acknowledge the evidence that antipsychotic drugs accumulate in synaptic vesicles and are secreted from these structures upon exocytosis, resulting in increased extracellular drug concentrations during neuronal activity, which in turn, inhibits electrically stimulated synaptic vesicle exocytosis in a dose-dependent manner 49 . We note from this study that at least 14 days of haloperidol treatment, using an identical drug delivery system to our own work appears to be necessary for elevated extracellular haloperidol levels following high K + stimulation 49 . In the current study, we exposed rats to an identical haloperidol dose Therefore, whilst additional experiments are required to definitively rule out any effect of antipsychotic-induced exocytosis on SV2A protein or ligand binding, the aforementioned findings suggest this is unlikely to be the case. We have amended the discussion to highlight these points as follows:
Antipsychotic drugs accumulate in synaptic vesicles and are secreted upon exocytosis, resulting in increased extracellular drug concentrations during neuronal activity and dosedependent inhibition of electrically stimulated synaptic vesicle exocytosis 49 , which could theoretically affect [ 11 C]UCB-J binding. At least 14 days of haloperidol treatment, using an identical drug delivery system to our own work, appears to be necessary for elevated extracellular haloperidol levels following high potassium stimulation 49 . In the current study, we exposed rats to an identical haloperidol dose as used in this study, as well as a higher dose of 2 mg/kg/d, for double that time, but did not find any change in SV2A protein or specific binding of [ 3 H]UCB-J. Therefore, whilst additional experiments are required to definitively rule out any effect of antipsychotic-induced vesicle exocytosis on SV2A protein or ligand binding, the aforementioned findings suggest this is unlikely to be the case.
Additional comments: 1) How were the secondary ROIs selected?
>> We have amended the method to make this clear as follows:
Furthermore, we performed an exploratory analysis to test whether effects are generalised to other brain regions (occipital, parietal and temporal lobes, dorsolateral prefrontal cortex, thalamus and amygdala) where structural and/or functional alterations have been identified in schizophrenia using in vivo neuroimaging [37] [38] [39] .
2) Where the groups matched for smoking status?
>> Subjects were not explicitly matched for smoking because there is no evidence that smoking affects SV2A levels or UCB-J uptake 6 . We have included information on smoking, conducted additional analyses to determine if this influenced findings and added a discussion of the implications. Please see responses to reviewer 1, point 2, for further details.
3) Figure 2, in the Western blot results the ratio of SV2A/GAPDH is relatively low, 0.05-

Did the authors also compare the uncorrected SV2A intensities?
>> We thank the reviewer for this constructive feedback. We have compared the uncorrected intensity of SV2A protein in the frontal cortex of the vehicle-and haloperidol-exposed rats. 
Comparison of uncorrected SV2A protein levels between vehicle-and haloperidol-exposed rats as measured by western blots
One-way ANOVA of SV2A intensity on western blot, not corrected for GAPDH signal, revealed no statistically significant differences between the groups (F 2,29 =0.37; p=0.70) 4) Line 296, the Vt value also includes the free radiotracer concentration, in addition to the specific and nonspecific binding.
>>We thank the reviewer for providing this important comment. We have updated the discussion to make this clear as shown in the following lines to reflect the contribution of free radiotracer concentration to V T .
It is important to recognise that V T includes both the concentration of radioligand specifically bound to SV2A and the non-specific uptake (that is, non-specifically bound and free radioligand concentrations).
5) Line 297, the proportion of Vt reflecting specific binding relates to the regional SV2A
density. In which brain region does 80% of Vt account for specific binding?
>>This is derived from occupancy plots of grey matter regions in the nonhuman primate brain 9 .
We have amended the discussion section to include the following:
Approximately 80% of [ 11 C]UCB-J V T in nonhuman primate grey matter regions is accounted for by specific binding 9, 45 , suggesting the lower values in schizophrenia are likely to be predominantly accounted for by differences in specific binding, but blocking studies in schizophrenia are needed to confirm this.
6) Line 353, should also refer to the loss of SV2A in MDD, reference 76.
>>We thank the reviewer for this recommendation, and have duly updated the discussion to that effect as follows:
UCB-J PET has demonstrated sensitivity to synaptic reductions in temporal lobe epilepsy and Alzheimer's disease 7, 18 , and has provided evidence consistent with synaptic alterations in affective disorders 6 .
7) Line 480, what time window corresponds to the 14th frame?
>> The 14 th frame is acquired 540-660 seconds into the scan. We have updated the methods to reflect this as follows:
PET images were registered to each subject's MRI image and corrected for motion using frame-to-frame rigid-body registration, with the 14 th frame (acquired 540-660 seconds into the scan) as the reference frame as this shows good anatomical delineation. PET images were registered to each subject's MRI image and corrected for motion using frame-to-frame rigid-body registration, with the 14 th frame (acquired 540-660 seconds into the scan) as the reference frame as this shows good anatomical delineation. Regional time activity curves (TACs) were generated for each ROI.
8) Line
Regional TAC and arterial input function data were analysed together using the one-tissue compartment model (1TCM), which has been shown to produce reliable estimates of >> We thank the author for this constructive feedback.
In both the human and animal experiments, there are no prior data upon which to base a power calculation, given that these are the first experiments comparing SV2A in the living human brain in healthy volunteers and patients with schizophrenia, and exploring the effects of antipsychotic drugs on SV2A in the rat brain. As such, power calculations were not performed. We have amended the paper to discuss power issues.
Please see our response to reviewer 1 (comment 5) for how we have addressed the lack of a group effect in hippocampal V T in the discussion of the amended manuscript. We have further amended our discussion section to state the following:
Notwithstanding this, our findings in study 1 and 2 suggest that antipsychotic medication exposure is unlikely to account for the lower [ 11 C]UCB-J binding in schizophrenia patients.
Nonetheless, future studies investigating SV2A in untreated, first-episode psychosis patients would be useful to test this further, and determine if SV2A changes occur early in the course of illness. It is also important to recognise that our study is only powered to detect a strong relationship with symptoms, so it remains possible that there is a relationship between V T and symptoms. Longitudinal studies and larger samples are needed to test the time course of alterations and their relationship with symptoms further. >> We thank the reviewer for this important comment. We agree that our findings can not exclude differences of lesser effect size. Moreover, we have conducted further analysis which also suggest the lack of significance in the hippocampus may be due to sensitivity (see response to reviewer 1 point 6).
Related to this point
We have therefore clarified the points made in the discussion as follows:
Moreover, in contrast to post-mortem studies, we were able to examine multiple regions in each individual, and find evidence for regional specificity, given the finding of a significant group-by-region of interest interaction effect.
Furthermore, we have amended the discussion to highlight that we cannot exclude a smaller difference in hippocampal [ 11 C]UCB-J V T (please see reply to reviewer 1, comment 6). >> We thank the reviewer for highlighting this important point. The same primary antibody was used for both the western blot data and fluorescence immunostaining (rabbit polyclonal α-SV2A; ab32942, Abcam, Cambridge, UK). The selectivity of this antibody has been previously confirmed by absence of staining on slices from SV2A KO mice 54 . In addition, the specificity of this antibody is confirmed by SV2A blocking peptides 54 . We apologise for this oversight and have now included the appropriate references in the Supplementary Methods as follows:
Sections were then incubated for 18h at 4°C with primary antibody (Rabbit-α-SV2A, Abcam ab32942; 1:1000) diluted in blocking solution supplemented with 0.02% sodium azide.
Specificity of the SV2A antibody in immunostaining has previously been verified using slices from SV2A KO mice, as well as SV2A blocking peptides 54 . Sections were then washed in PBS (3 x 10') and incubated for 2h in secondary antibody solution.
With regard to the specificity of the We apologise that this was not clearer and now include the appropriate references in the methods as shown below, and discuss the specificity of UCB-J further in the discussion (see response to reviewer 1, point 6):
All participants underwent a PET scan with [ 11 C]UCB-J, a radioligand specific for SV2A 7, 9, 15 .
and Individual slides containing 10-12 adjacent tissue sections at 500 µm interval were then preincubated in assay buffer (50mM Tris Base, 140mM NaCl, 1.5mM MgCl2, 5mM KCl, >> Please see our response to reviewer 1, comment 2.
9. The groups are well matched in terms of age and gender. However, both groups are predominantly male. Were sampling procedures biased toward men?
>> We thank the reviewer for highlighting this important point. There was no explicit bias towards recruiting males in the protocol. The imbalance may reflect the fact schizophrenia has a male preponderance 57, 58 , and the requirement for females to have a negative pregnancy screen and be on effective contraception during the study, which excludes some women. We have amended the discussion to discuss this issue as follows:
In study 1, the volunteers are mostly male (n = 15 of 18 per group), which may limit generalisations to female patients. However, previous work has not found an effect of sex on All references to the sample size have been amended to n = 18, 15 male and 3 female per group.
Results
[ 11 C]UCB-J V T across groups in a priori ROIs
There was a significant effect of group (F 1, 34 = 6.170, p=0.02) and region of interest (ROI; proposed that excessive pruning of dendritic spines contributes to deficits in grey matter volumes in schizophrenia, given the association between grey matter volumes measured by VBM and dendritic spine density 60 . Functional dysconnectivity may reflect impaired integration of neuronal systems secondary to synaptic pathology 14 . Structural and functional alterations may provide indirect evidence for altered synaptic function but we acknowledge there may be other explanations for these findings. We apologise for the lack of clarity and have updated the introduction to read:
Further, albeit indirect, evidence for altered synaptic function comes from in vivo neuroimaging studies which show lower brain volumes 37, 43, 61 and altered functional connectivity in schizophrenia relative to controls [62] [63] [64] , which may reflect altered synaptic density and/or function in schizophrenia (although there are other potential explanations for these findings). >> We thank the reviewer for this important comment, and apologise for our lack of clarity.
Line 81 -
We have amended the paper to clarify this. Please see our response to reviewer 1 (comment 4). >>We elected to explore the frontal cortex, ACC and hippocampus as paired structures on the basis of the meta-analysed postmortem literature which demonstrated reductions in synaptophysin in schizophrenia in those regions as paired structures 21 . We did not hypothesise lateralised effects and hypothesised, therefore, only that there would be reductions in SV2A in regions analogous to the those explored in the meta-analytic findings.
15. Line 85 -The meaning of "indirectly associated" is unclear.
>>We thank the reviewer for this comment and apologise for the lack of clarity here. We have amended the text to state "inversely associated".
16. Line 108 -The authors state that "all volunteers with schizophrenia were on dopamine D2 receptor antagonist medication". This is technically not true, since one patient is on a partial agonist, aripiprazole. It might be better to use a more general term, such as "antipsychotics".
>>We thank the reviewer for drawing our attention to this. In light of this, we have amended the manuscript such that the term "antipsychotic drug" is used now to refer to the medications taken by the group collectively as suggested by the reviewer. >> There is no simple answer to making age comparisons between humans and the animal models. We and others have referenced the work of Quinn 65 to address this issue. For adult rats, Quinn suggests that 11.8 days is equivalent to 1 human year, hence a 28-day exposure could be simply interpreted as equivalent to 2.4 human years of exposure. This is very likely a gross oversimplification and differences in anatomy, physiology, and developmental biology must be taken into consideration when analysing the results of any experiment. It is noTable that as only 14 days of antipsychotic treatment (using identical doses and mode of administration to our work) is necessary to induce both behavioural and synaptic alterations in naïve male rats 49, 66 . Yet, after 28 days exposure in our study (double the duration) we saw no effect on SV2A protein expression or ligand binding. Nevertheless, we acknowledge that future studies should seek to validate the effect of both acute and longer duration of exposure to antipsychotic drugs to allow a definitive conclusion on this matter.
We have amended the discussion to discuss this issue as follows:
We examined the effects of a 28-day exposure (roughly equivalent to 2.4 human years 67 , although this is a very simplified model). Most of the volunteers with schizophrenia in this study had taken antipsychotic drugs longer than this.
Lines 421-422 -Please specify what is meant by "schizophrenia spectrum disorders"
>> As defined in DSM-5, schizophrenia spectrum disorders includes schizophrenia and other schizophreniform psychotic disorders.
As all our patient subjects met DSM-5 criteria for schizophrenia, we have amended those lines to refer to schizophrenia only. >>We apologise for the lack of clarity regarding how the diagnosis was determined for volunteers with schizophrenia, and have amended the methods section as follows:
Volunteers with schizophrenia underwent a psychiatric symptom assessment by a psychiatrist using the Positive and Negative Syndrome Scale (PANSS) 53 to assess symptom severity and the Structured Clinical Interview for DSM-5 to confirm the diagnosis and to assess for psychiatric co-morbidities. Table 1 and we have amended the discussion to consider this as follows:
Line 777 (Supplemental
Six patients were taking clozapine, which, as this is generally reserved for patients whose illness is antipsychotic treatment resistant 68 , could indicate a third of our sample met criteria for treatment resistant schizophrenia, although this was not formally assessed. Population studies indicate that antipsychotic treatment resistance is seen in about one third of chronic and about 20% of first-episode patients 69, 70 , indicating our sample is representative of chronic schizophrenia but less representative of first-episode patients in this respect. We did not find a significant difference in V T between clozapine treated and non-clozapine treated patients, although, as the study was not designed to test differences between these groups, it would be interesting to test this in a further study.
Below are detailed additional alterations made by the authors:
>> We have updated the authors list to include an additional author, whose name was omitted from the original manuscript in error.
>>We have added group parametric [ 11 C]UCB-J V T images as Figure 2 , to provide a visual aid for the the viewer of the areas where there are differences in V T .
>>All references to the sample size (n = 16, 15 male and 1 female per group) have been amended (to n = 18, 15 male and 3 female per group).
